Geron reports Q2 2026 results as RYTELO revenue climbs to $57.5 million
The company reiterated its full-year revenue and expense guidance while highlighting new real-world and Phase 2 myelofibrosis data and progress on its Phase 3 IMpactMF trial.
SEC filing